Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
Propanc Biopharma is advancing preparations for its planned Phase 1b first-in-human study of PRP (PPC-001), targeting up to 50 advanced cancer patients with solid tumors. Key workstreams underway include clinical protocol and Investigator's Brochure finalization targeted for early November 2026, site feasibility work in Australia, vendor selection, and ethics submissions planned for November 2026 with regulatory activities in January 2027. The company targets February 2027 for first clinical site initiation and first patient screening, subject to completing clinical, regulatory, ethics and operational requirements. PRP holds FDA Orphan Drug Designation in pancreatic cancer.
Key figures
- Drug Name
- PRP (PPC-001)
- Phase Of Trial
- Phase 1b
- Study type
- multicenter, open-label, two-part dose escalation and expansion in advanced or metastatic solid tumors
- Planned patients
- up to 50 advanced cancer patients
- First site initiation target
- February 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.